← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,106	+2	+0.1%	$179B
2	2 Pfizer PFE $166B	1,888	+11	+0.6%	$147B
3	3 Merck MRK $364B	1,726	+14	+0.8%	$120B
4	4 AbbVie ABBV $501B	1,654	+53	+3%	$80.6B
5	5 Gilead Sciences GILD $190B	1,561	+67	+4%	$141B
6	6 Bristol-Myers Squibb BMY $121B	1,448	-2	-0.1%	$81B
7	7 Amgen AMGN $230B	1,367	+22	+2%	$93.7B
8	8 Novartis NVS $279B	945	+5	+0.5%	$23.2B
9	9 GSK GSK $95.9B	721	-20	-3%	$9.73B
10	10 Regeneron Pharmaceuticals REGN $80.1B	541	+32	+6%	$37.7B
11	11 AstraZeneca AZN $251B	376	-10	-3%	$6.27B
12	12 Jazz Pharmaceuticals JAZZ $13.6B	374	+19	+5%	$9.88B
13	13 Incyte INCY $22.6B	334	+30	+10%	$17.5B
14	14 Myriad Genetics MYGN $397M	235	-17	-7%	$3.17B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	220	+17	+8%	$6.18B
16	16 Opko Health OPK $1.02B	219	+28	+15%	$1.38B
17	17 DELISTED Assertio ASRT	204	+8	+4%	$1.42B
18	18 DELISTED Exact Sciences EXAS	203	+21	+12%	$2.62B
19	19 Puma Biotechnology PBYI $527M	198	-1	-0.5%	$3.55B
20	CLVS 20 DELISTED Clovis Oncology, Inc. CLVS	177	+25	+16%	$2.84B
21	21 Precigen PGEN $2.64B	173	+19	+12%	$4.63B
22	22 Halozyme HALO $13.3B	158	+21	+15%	$2.2B
23	23 DELISTED Chimerix, Inc. CMRX	156	+14	+10%	$1.89B
24	24 DELISTED Merrimack Pharmaceuticals, Inc. MACK	150	-2	-1%	$932M
25	25 DELISTED Lumos Pharma, Inc. Common Stock LUMO	145	+21	+17%	$703M